23andMe Holding Co. (ME)
|Net Income (ttm)||-314.54M|
|Day's Range||2.78 - 2.92|
|52-Week Range||2.12 - 8.95|
|Price Target||5.69 (+102.5%)|
|Earnings Date||Nov 7, 2022|
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeuti... [Read more]
In 2021, ME's revenue was $271.89 million, an increase of 11.47% compared to the previous year's $243.92 million. Losses were -$217.49 million, 18.4% more than in 2020.Financial Statements
According to 11 analysts, the average rating for ME stock is "Buy." The 12-month stock price forecast is 5.69, which is an increase of 102.49% from the latest price.
23andme founder on the future of health care
This segment originally aired on November 15, 2022. 23andMe Co-Founder and CEO Anne Wojcicki sits down with Yahoo Finance's Anjalee Khemlani at the HLTH conference to discuss the slowdown in growth, con...
Second quarter revenue grew 37% to $76 million Consumer revenue grew 27% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD2...
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity The presentation outlines ...
These companies haven't performed as well as I thought they would, but I don't plan to sell.
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medi...
FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for confirmatory...
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, ...
They're both using unique and highly efficient approaches to developing and deploying their medicines.
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, ...
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1...
Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignancies Poster to provide details on study design and expansion phase for ong...
Reddit stocks have been so successful (or at least intriguing) that Reddit has quickly become an investing hub. The site has a huge community of investors and traders who use it as a platform for their ...
Chu brings over two decades of experience in product management, design and strategy, as well as expertise with navigating complex industries Chu brings over two decades of experience in product managem...
Ancestry CEO on 23andMe: ‘I think their product is really incredible'
Ancestry CEO Deb Liu joins 'Influencers with Andy Serwer' to discuss the business of DNA and how Ancestry.com competes with other genealogy products.
Genetics testing provider 23andMe said its chief financial officer will leave the company next month after four years with the company. Steve Schoch notified 23andMe of his resignation earlier this week...
Source: nevodka / Shutterstock.com 23andMe (NASDAQ: ME ) is preparing for a major change at the executive level. Today, the firm announced that CFO Steven Schoch is planning to resign.
Shares of 23andMe Holding Co. ME, +1.95% were falling more than 7% in premarket trading Friday after the DNA-testing company disclosed that Chief Financial Officer Stevem Schoch was resigning from the c...
Investors continue to slowly move away from worries about the economy, inflation, and interest rates, sending growth stocks higher. It's not all good news and positivity, though.
23andMe will appeal to more and more masses as genetics becomes core part of health care, says CEO
Anne Wojcicki, 23andMe co-founder and CEO, joins 'TechCheck' to discuss the economic impact on 23andMe's business, what the company needs to do to reach the biggest market possible and more.
First quarter revenue grew 9% to $64.5 million Consumer revenue grew 17% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance
Trading volume is surging in the hours leading up to its quarterly financial report.
SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financi...
23andMe CEO on Telehealth: Sun Valley
23andMe CEO Anne Wojcicki speaks with Ed Ludlow at the Allen & Company Sun Valley Conference about healthcare trends, findings from a long covid study, and a telehealth acquisition.
The genetics company misses on both the top and bottom lines in its fourth quarter.
Shares of 23andMe Holding Co. ME, fell almost 7% in after-hours trading after the genetic-testing company saw its loss widen for the fiscal fourth quarter, and issued guidance that assumes the loss will...